Intermountain Precision Genomics and Asia Genomics are joining forces to deliver personalized medicine. First up is a test in Southeast Asia.

Under the collaboration deal, the first for Intermountain Precision Genomics outside of the U.S., Asia Genomics is contracting with Intermountain Precision Genomics to offer ICG100 testing.

The Intermountain Precision Genomics ICG100 test is next generation sequencing that identifies mutations within a person’s cancer to identify specific DNA targets for personalized drug treatments. The IGC100 test is approved for late stage cancer patients who have failed a traditional treatment method, offering new hope when traditional treatments don’t work.

Asia Genomics has been offering various types of genomic tests in the healthcare environment since 2014. The tests primarily center on reproductive health and cancer care.

“Leveraging Intermountain Precision Genomics’ years of experience in cancer research, diagnosis and treatment, we aim to improve survival and quality of life for cancer patients in Asia,” Wong Mun-Yew, a physician and CEO and founder of Asia Genomics, said in a statement.

“We are pleased to partner with Asia Genomics to help extend life and improve quality of life for late-stage cancer patients across Southeast Asia,” Terri Kane, vice president of Intermountain Healthcare’s Southwest Region, which includes Intermountain Precision Genomics, said in a statement. “Targeted therapies are the most effective treatment for late-stage cancer patients, and we look forward to this partnership positively impacting the way patients receive care around the world.”